Back to Search
Start Over
Efficacy of tasquinimod in men with metastatic castration-resistant prostate cancer: A meta-analysis of randomized controlled trials
- Source :
- Medicine
- Publication Year :
- 2018
-
Abstract
- Supplemental Digital Content is available in the text<br />Background: Tasquinimod is an oral quinoline-3-carboxamide derivative for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Tasquinimod has antiangiogenic, immunomodulatory, and antimetastatic properties, but it is also associated with toxicities, including skeletal pain, digestive disorders, fatigue, insomnia, and mental disorders. We aimed to perform a meta-analysis to evaluate the efficacy, safety, and long-term survival for tasquinimod in patients with mCRPC. Methods: Searches were carried out in PubMed, Embase, and the Cochrane Library. Eligible articles included randomized clinical trials (RCTs) comparing systemic or combination therapy (excluding primary or secondary androgen deprivation therapy, bone protective agents, or radionuclides) with placebo in men with mCRPC. Results: Three RCTs were selected for final evaluation. The pooled results from the 3 studies indicated that tasquinimod was associated with good radiologic progression-free survival (rPFS) in mCRPC. For adverse effects (AEs), the results of meta-analysis indicated that patients with mCRPC who received tasquinimod had obvious anemia (risk ratio (RR) 1.35, 95% confidence interval (CI) 1.06–1.73, P = .02), back pain (RR: 1.57, 95% CI: 1.01–2.47, P = .05), pain in the extremities (RR: 1.90, 95% CI: 1.14–3.17, P = .01), insomnia (RR: 1.50, 95% CI: 1.03–2.17, P = .03), vomiting (RR: 1.52, 95% CI: 1.04–2.21, P = .03), and peripheral edema (RR: 1.52, 95% CI: 1.03–2.23, P = .03). Conclusions: Tasquinimod is associated with better rPFS in mCRPC. The toxicity of tasquinimod requires further investigation, it is not recommended for routine clinical use.
- Subjects :
- 0301 basic medicine
Oncology
Male
medicine.medical_specialty
MEDLINE
Angiogenesis Inhibitors
Castration resistant
Quinolones
tasquinimod
law.invention
Tasquinimod
03 medical and health sciences
Prostate cancer
0302 clinical medicine
Text mining
Randomized controlled trial
law
Internal medicine
Medicine
Humans
Survival rate
Randomized Controlled Trials as Topic
business.industry
General Medicine
medicine.disease
Survival Rate
meta-analysis
Prostatic Neoplasms, Castration-Resistant
030104 developmental biology
Treatment Outcome
metastatic castration-resistant prostate cancer
030220 oncology & carcinogenesis
Meta-analysis
ComputingMethodologies_DOCUMENTANDTEXTPROCESSING
business
Systematic Review and Meta-Analysis
Research Article
Subjects
Details
- ISSN :
- 15365964
- Volume :
- 97
- Issue :
- 46
- Database :
- OpenAIRE
- Journal :
- Medicine
- Accession number :
- edsair.doi.dedup.....794f982dd4ec205a289c7740d93418d4